- Home
- AIG vs ONC Comparison
AIG vs ONC Comparison
Compare AIG & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIG
- ONC
- Stock Information
- Founded
- AIG 1919
- ONC 2010
- Country
- AIG United States
- ONC Switzerland
- Employees
- AIG N/A
- ONC N/A
- Industry
- AIG Life Insurance
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- AIG Finance
- ONC Health Care
- Exchange
- AIG Nasdaq
- ONC Nasdaq
- Market Cap
- AIG 45.2B
- ONC 37.3B
- IPO Year
- AIG N/A
- ONC N/A
- Fundamental
- Price
- AIG $81.73
- ONC $318.73
- Analyst Decision
- AIG Buy
- ONC Strong Buy
- Analyst Count
- AIG 12
- ONC 9
- Target Price
- AIG $87.75
- ONC $335.78
- AVG Volume (30 Days)
- AIG 3.7M
- ONC 335.8K
- Earning Date
- AIG 11-03-2025
- ONC 08-06-2025
- Dividend Yield
- AIG 2.20%
- ONC N/A
- EPS Growth
- AIG N/A
- ONC N/A
- EPS
- AIG 5.22
- ONC N/A
- Revenue
- AIG $27,396,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- AIG $2.98
- ONC $875.58
- Revenue Next Year
- AIG $2.79
- ONC $20.99
- P/E Ratio
- AIG $15.64
- ONC N/A
- Revenue Growth
- AIG 1.17
- ONC 47.33
- 52 Week Low
- AIG $69.24
- ONC $170.99
- 52 Week High
- AIG $88.07
- ONC $339.86
- Technical
- Relative Strength Index (RSI)
- AIG 54.30
- ONC 56.95
- Support Level
- AIG $79.90
- ONC $295.22
- Resistance Level
- AIG $83.78
- ONC $339.86
- Average True Range (ATR)
- AIG 0.97
- ONC 7.67
- MACD
- AIG 0.05
- ONC 0.52
- Stochastic Oscillator
- AIG 53.62
- ONC 52.67
About AIG American International Group Inc. New
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a minority stake.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.